Comparison of Transient Elastography and Liver Biopsy in Assessing Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a common cause of chronic liver disease. Ultrasound-based transient elastography (TE) or TE of the liver is a noninvasive tool for effectively evaluating liver stiffness and fibrosis. The study aimed to compare the accuracy of TE as assessed by Fibroscan with liver biopsy in staging fibrosis in patients with NAFLD. Consecutive NAFLD patients (N = 72) were prospectively enrolled. TE evaluation was performed with Fibroscan and compared with liver biopsy, which is a reference standard. Fibrosis was staged according to the METAVIR scoring system (Meta-analysis of Histological Data in Viral Hepatitis). TE scores and biopsy-related fibrosis stages were correlated. Diagnostic accuracy (sensitivity, specificity, positive and negative predictive values) of TE was evaluated. Data were analyzed using software R v3.6.3. Liver biopsy showed that 36.11% of patients did not exhibit fibrosis, whereas 25, 16.67, 15.28, and 6.94% of patients had stage F1 (portal/mild fibrosis), F2 (periportal/moderate fibrosis), F3 (bridging/severe fibrosis), and F4 (cirrhosis/advanced fibrosis), respectively. TE showed that 50% of patients had cirrhosis, whereas 20.83,15.28, and 13.86% of patients had mild, moderate, and severe fibrosis, respectively. TE had 71% accuracy, 89% sensitivity, and 38% specificity in diagnosing the severity of fibrosis. Hence, it can be implemented as a noninvasive alternative diagnostic tool for understanding the severity of fibrosis in patients with NAFLD. Moreover, it can also be used for quick early diagnosis of NAFLD, reliable staging of fibrosis, and understanding the need for liver transplantation in patients with NAFLD.
Keywords
How to Cite
References
Andronescu CI, Purcarea MR, Babes PA. Nonalcoholic fatty liver disease: epidemiology, pathogenesis, and therapeutic implications. J Med Life. 2018;11(1):20–23.
Mikolasevic I, Milic S, Wensveen TT, Grgic I, Jakopcic I, Stimac D, et al. Nonalcoholic fatty liver disease – A multisystem disease? World J Gastroenterol. 2016;22(43):9488. http://dx.doi.org/10.3748/wjg.v22.i43.9488
Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10(11):686–90. http://dx.doi.org/10.1038/nrgastro.2013.171
Kneeman JM, Misdraji J, Corey KE. Secondary causes of nonalcoholic fatty liver disease. Thera Adv Gastroenterol. 2012;5(3):199–207. http://dx.doi.org/10.1177/1756283X11430859
Alkhouri N, McCullough AJ. Noninvasive diagnosis of NASH and liver fibrosis within the spectrum of NAFLD. Gastroenterol Hepatol. 2012;8(10):661.
National Guideline Centre (UK). Non-Alcoholic Fatty Liver Disease: Assessment and Management. London: National Institute for Health and Care Excellence (UK); 2016 Jul. (NICE Guideline, No. 49) Available from: https://www.ncbi.nlm.nih.gov/books/NBK374135/
Fallatah HI. Noninvasive biomarkers of liver fibrosis: An overview. Adv Hepatol. 2014;2014:357287. http://dx.doi.org/10.1155/2014/357287
Maklad S, Esmat G, Hassan E, Attalah M, Zeid AA. Liver biopsy and FibroScan to detect early histopathological changes in chronic HBV patients not candidate for treatment. Gastroenterol Res. 2014;7(2):56. http://dx.doi.org/10.14740/gr597w
El Saadany S, Soliman H, Ziada DH, Hamisa M, Hefeda M, Selim A, et al. Fibroscan versus liver biopsy in the evaluation of response among the Egyptian HCV infected patients to treatment. Egypt J Radio Nuc Med. 2016;47(1):1–7. http://dx.doi.org/10.1016/j.ejrnm.2015.12.007
Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine. 2016;95(5): pe2630. http://dx.doi.org/10.1097/MD.0000000000002630
Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013;35(2):121. http://dx.doi.org/10.4103/0253-7176.116232
Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): A prospective study. Gut. 2016;55(3):403–8. http://dx.doi.org/10.1136/gut.2005.069153
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74. http://dx.doi.org/10.1111/j.15720241.1999.01377.x
Pais RA, Lups¸or MO, Poanta? LA, Silaghi AL, Rusu ML, Badea R, Dumitras¸cu DL. Liver biopsy versus noninvasive methods – Fibroscan and fibrotest in the diagnosis of non-alcoholic fatty liver disease: A review of the literature. Rom J Intern Med. 2009;47(4):331–40.
Perumpail BJ, Khan MA, Yoo ER, Cholankeril G, Kim D, Ahmed A. Clinical epidemiology, and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017;23(47):8263. http://dx.doi.org/10.3748/wjg.v23.i47.8263
Tovo CV, Villela-Nogueira CA, Leite NC, Panke CL, Port GZ, Fernandes S, et al. Transient hepatic elastography has the best performance to evaluate liver fibrosis in non-alcoholic fatty liver disease (NAFLD). Ann Hepatol. 2019;18(3):445–9. http://dx.doi.org/10.1016/j.aohep.2018.09.003
Hashemi SA, Alavian SM, Gholami-Fesharaki M. Assessment of transient elastography (FibroScan) for diagnosis of fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Caspian J Intern Med. 2016;7(4):242.
Vispo E, Barreiro P, Del Valle J, Maida I, de Ledinghen V, Quereda C, et al. Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. Antivir Ther. 2009;14(2):187–93.
Lucidarme D, Foucher J, Le Bail B, Vergniol J, Castera L, Duburque C, et al. Factors of accuracy of transient elastography (fibroscan) for the diagnosis of liver fibrosis in chronic hepatitis C. Hepatol. 2006; 49(4):1083–9. http://dx.doi.org/10.1002/hep.22748
Sporea I, S¸irli R, Deleanu A, Tudora A, Curescu M, Cornianu M, Laza?r D. Comparison of the liver stiffness measurement by transient elastography with the liver biopsy. World J Gastroenterol. 2008;14(42):6513–17. http://dx.doi.org/10.3748/wjg.14.6513
Fujimori N, Tanaka N, Shibata S, Sano K, Yamazaki T, Sekiguchi T, et al. Controlled attenuation parameter is correlated with actual hepatic fat content in patients with non-alcoholic fatty liver disease with none-to-mild obesity and liver fibrosis. Hepatol Res. 2016;46(10):1019–27. http://dx.doi. org/10.1111/hepr.12649
Foucher J, Castéra L, Bernard PH, Adhoute X, Laharie D, Bertet J, et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol. 2016;18(4):411–12. http://dx.doi.org/10.1097/00042737-200604000-00015
Angulo P. Nonalcoholic fatty liver disease. N Eng J Med. 2002;346(16):1221–31. http://dx.doi.org/10.1056/ NEJMra011775
Farrell GC. Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia–Pacific region? J Gastroenterol Hepatol. 2003;18(2):124–38. http://dx.doi.org/10.1046/j.1440-1746.2003.02989.x
Bang KB, Cho YK. Comorbidities and metabolic derangement of NAFLD. J Lifestyle Med. 2015;5(1):7. http://dx.doi.org/10.15280/jlm.2015.5.1.7
Corey KE, Vuppalanchi R. Assessment, and management of comorbidities (including cardiovascular disease) in patients with nonalcoholic fatty liver disease. Clin Liver Dis. 2012;1(4):114. http://dx.doi.org/10.1002/cld.26
Fibroscan predicts liver disease progression better than biopsy [Internet]. 2013. Available from: https://www.hepmag.com/article/Fibroscan-biopsy-24237-1656971490
Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Eng J Med. 2011;344(7):495–500. http://dx.doi.org/10.1056/NEJM2001021 53440706
Zachry WM. Abstract 27. Presented at: American College of Gastroenterology Annual Scientific Meeting; Philadelphia, PA; 2017.
Al Ghamdi MH, Fallatah HI, Akbar HO. Transient elastography (Fibroscan) compared to diagnostic endoscopy in the diagnosis of varices in patients with cirrhosis. Science. 2016;5(6):55–9. http://dx.doi.org/10.11648/j.sjcm.20160506.13
Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. Hepatol. 2003;32(3):477–81. http://dx.doi.org/10.1053/jhep.2000.16602
Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol Hepatol. 2000;14(6):543–8. http://dx.doi. org/10.1155/2000/107982
Copyright and licence
Copyright (c) 2021 Gaurav Bachhav, Lokesh Locheruvapalli Venkateshappa, Balekuduru Avinash, Manjunath Patil, Satyaprakash Bonthala Subbara , Sindhuvalada Karnam Ravikiran

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

